

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Study protocol for a single-center randomized controlled trial to investigate the effect of lung recruitment in pediatric patients after cardiac surgery

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063278
Article Type:	Protocol
Date Submitted by the Author:	29-Mar-2022
Complete List of Authors:	Deng, Ni; Sichuan University West China Hospital Gu, Miaomiao; Sichuan University West China Hospital Xia, Wenxi; Sichuan University West China Hospital Deng, Lijing; Sichuan University West China Hospital, Department of Critical Care Medicine Liang, Guopeng; Sichuan University West China Hospital
Keywords:	Cardiac surgery < SURGERY, Paediatric intensive & critical care < ANAESTHETICS, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Paediatric intensive & critical care < INTENSIVE & CRITICAL CARE, Paediatric intensive & critical care < PAEDIATRICS, Paediatric cardiac surgery < PAEDIATRIC SURGERY
	1



2	
3	
4	Study protocol for a single-center randomized controlled trial to investigate the
5	
6	offect of lung reconsistment in redictric retients often condice surgery
7	effect of lung recruitment in pediatric patients after cardiac surgery
8	
9	Ni Deng ¹ ,Miaomiao Gu ¹ ,Wenxi Xia,Lijing Deng*,Guopeng Liang*
10	
11	
12	Ni Deng Department of Critical Care Medicine, West China Hospital of Sichuan
13	
14	University,Chengdu, China
15	
16	
17	Miaomiao Gu Department of Critical Care Medicine, West China Hospital of Sichuan
18	
19	University,Chengdu, China
20	omversity; enenguu; emma
21	
22	Wenxi Xia Department of Critical Care Medicine, West China Hospital of Sichuan
23	
24	University,Chengdu, China
25	
26	
27	Lijing Deng Department of Critical Care Medicine, West China Hospital of Sichuan
28	
29	
30	University,Chengdu, China
31	
32	Guopeng Liang Department of Critical Care Medicine, West China Hospital of Sichuan
33	
34 35	
36	University,Chengdu, China
37	
38	¹ Both authors contributed equally to this paper
39	
40	
41	* Both corresponding authors contributed equally to this paper
42	
43	
44	
45	
46	Correspondence to Dr Lijing Deng dengni-2004@163.com
47	
48	Dr Guopeng Liang liangguopeng007@163.com
49	Di Guopeng Liang hangguopengoo/@105.com
50	
51	Key words: pediatric, lung recruitment, cardiac surgery, hypoxemic respiratory failure
52	
53	
54	
55	
56	I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work
57	
58	
59	(as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for
60	

contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Abstract

Introduction

A number of published studies have revealed that lung recruitment can improve oxygenation, shorten the duration of mechanical ventilation (MV), and decrease mortality in adults with acute hypoxemic respiratory failure, especially patients with acute respiratory distress syndrome. However, few articles have assessed lung recruitment in pediatric patients, especially after cardiac surgery. This clinical trial aimed to determine whether lung recruitment can reduce the duration of MV in pediatric patients with hypoxemic respiratory failure after cardiac surgery.

Method and analysis

In this trial, we will randomly assign 234 pediatric patients (aged 28 days to 14 years) within 72 hours after cardiac surgery with an arterial oxygen tension (PaO₂) to fraction of inspired oxygen (FiO₂) ratio (PaO₂/FiO₂) of \leq 300 to either a lung recruitment group or a conventional group. The primary endpoint will be the duration of MV. The secondary endpoints will be ventilator-free days, PaO₂/FiO₂, respiratory system compliance, duration of non-invasive ventilation, reintubation rate, length of ICU stay, length of hospital stay, occurrence of serious adverse events (barotrauma, persistent hypotension and arrhythmia), postoperative pulmonary complications.

Ethics and dissemination

The ethics committee of West China Hospital of Sichuan University granted ethics approval for this study (20/8/2019). The results will be published in peer-reviewed journals and presented at conferences.

Trial registration number: ChiCTR1900025990

Strengths and limitations of this study:

1. The protocol will be a randomized controlled trial, so the reliability of the results will be very high.

2. The incidence of hypoxic respiratory failure in pediatrics with congenital heart disease after surgery

is low, and it will take a long time to achieve the expected sample size.

3. Because of lack of sufficient research data on lung recruitment in pediatrics, we do not know whether

the methods, parameters of RM and the indications of repeat RM are reasonable, which may affect the

outcome of patients.

Introduction

Hypoxemic respiratory failure, especially acute respiratory distress syndrome (ARDS) after cardiac surgery, is the main cause of prolonged mechanical ventilation (MV). General anesthesia, extracorporeal circulation, procedure-related lung injury, and inappropriate ventilation strategies are risk factors for hypoxemic respiratory failure in patients after cardiac surgery ^[1]. A recent prospective multi-center study diagnosed 10% of patients with ARDS after cardiac surgery ^[2]. Compared with adults, pediatric patients are more likely to suffer from hypoxemic respiratory failure after cardiac surgery ^[2].

Lung recruitment maneuvers(RM) can prevent alveolar collapse, improve oxygenation, and enhance respiratory system compliance by temporarily increasing transpulmonary pressure ^[3]. Over the past two decades, a number of studies have confirmed the effectiveness of lung recruitment for improving oxygenation, reducing the duration of MV, and decreasing mortality in adults with hypoxemic respiratory failure, especially those diagnosed with ARDS ^[4-8]. However, studies investigating the clinical use of lung recruitment in pediatric patients are limited. Although several studies have reported that lung recruitment maneuvers combined with positive end-expiratory pressure (PEEP) titration can improve oxygenation and decrease the partial pressure of carbon dioxide in arterial blood (PaCO₂) in pediatric patients with hypoxemic respiratory failure, no studies have assessed the effectiveness of lung recruitment in reducing the duration of MV in pediatric patients after cardiac surgery ^[9-19].

As a result, this single-center study was designed to determine whether lung recruitment maneuvers combined with PEEP titration can reduce the duration of MV and intensive care unit (ICU) stay, as well as all-cause mortality rate, in pediatric patients after cardiac surgery.

Methods

Study setting

 This study adopted a prospective, single-center, parallel group, randomized, controlled design and is ongoing at West China Hospital of Sichuan University (January 2020 to December 2022). The ethics committee of West China Hospital of Sichuan University granted ethics approval (20/8/2019).

Eligibility criteria

The inclusion criteria are as follows: 1) pediatric patients after cardiac surgery whose cardiac anatomical deficiency was completely corrected after surgery; 2) pediatric patients aged 28 days to 14 years; 3) partial pressure of oxygen (PaO₂) to fraction of inspired oxygen (FiO₂) ratio (PaO₂/FiO₂) of <300 with PEEP \geq 5cm H₂O within 72 hours after surgery.

The exclusion criteria are as follows: 1) pediatric patients deemed unsuitable for lung recruitment by the attending intensivist; 2) presence of an uncuffed endotracheal tube; 3) pneumothorax; 4) severe hemodynamic instability (requiring norepinephrine >0.2 μ g/kg/min or epinephrine >0.2 μ g/kg/min); 5) lack of consent from the next of kin; 6) diaphragmatic paralysis; 7) central nervous system complications; 8) raised intracranial pressure (>20 mmHg); 9) bronchopleural fistula;10)intracardiac shunt.

Participant selection and recruitment

Before identifying and screening patients for eligibility, all patients will be initially ventilated with synchronized intermittent mandatory ventilation-pressure control (SIMV-PC) using a Puritan BennettTM 840 Ventilator (Covidien, Medtronic Inc., Minneapolis, MN) for 30 minutes (Figure 1). Then the first arterial blood gas analysis will be obtained. Specific ventilator settings are described in Table 1. PetCO₂, an index of PaCO₂, will be monitored using a carbon dioxide (CO₂) analyzer. Informed consent will be obtained by the doctor in charge. All information will be transferred into an electronic database so that the trial office can monitor recruitment and refusal rates.

1	
2	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	
4 5	
5	
7	
, 8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
24	
25	
26	
20 21 22 23 24 25 26 27 28	
28	
29	
30	
31	
31 32 33 34 35 36 37 29	
33	
34	
35 26	
27	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49 50	
50 51	
51 52	
52 53	
54	
55	
56	
57	
58	
59	
60	

Age	Mode	F	Ti	Pi	Ps	FiO ₂	PEEP	vsens
4 weeks < age ≤ 1 year	SIMV-PC	30	0.67	12	10	50%	5	1
1 year < age \leq 3 years	SIMV-PC	25	0.80	12	10	50%	5	1
3 years < age \leq 12 years	SIMV-PC	20	0.86	12	10	50%	5	1
Age > 12 years	SIMV-PC	15	1.0	12	10	50%	5	1

Intervention

The intervention group comprises patients who have undergone lung recruitment and PEEP titration. The control group comprises patients who have undergone conventional MV. Patients will be prospectively followed from the day of enrollment for at least 28 days or until discharge, whichever comes first.

In both groups, the ventilation and oxygenation goals are as follows: 1) arterial pH, 7.35~7.45; PaCO₂, 35–45 mm Hg; 2) SpO₂, 92%–97% for patients with a PEEP <10 cm H₂O and 88%–92% for patients with a PEEP >10 cm H₂O. To prevent ventilator-induced lung injury, the general principle of ventilator setting includes limiting driving pressure to 15cm H₂O, plateau pressure to 28cm H₂O (allowing for slightly higher plateau pressures (29–32 cm H₂O) for patients with increased chest wall elastance), PEEP to 20 cm H₂O. In patients with severe hypoxemia, FiO₂ can be more than 60%.^[20] High-frequency oscillatory ventilation (HFOV) should be considered as an alternative ventilatory mode in patients in whom plateau airway pressures exceed 28 cm H₂O in the absence of clinical evidence of reduced chest wall compliance. ECMO may be considered in patients whose ventilation parameters have been maximized but still cannot achieve adequate gas exchange.^[13]

In the conventional group, PEEP and FiO_2 will be adjusted according to the PEEP-FiO₂ table (Table 2) to achieve the target SpO₂ described above. In the lung recruitment group, RM and decremental PEEP

titration will be performed immediately after enrollment and applied at least twice a day until extubation. RM will also be repeated if patients meet any of the following three conditions: 1) $PaO_2 \le 60 \text{ mmHg}$; 2) $SpO_2 \le 88\%$; 3) $PaCO_2 > 45 \text{ mmHg}$. Additionally, physicians will apply routine care interventions for the general management of critically ill patients, according to current guideline standards.

Table 2. PE	EP-FiO ₂	table
-------------	----------------------------	-------

FiO ₂	РЕЕР	Adjustment
$FiO_2 \leq 40\%$	$PEEP \le 8 \text{ cm } H_2O$	Increase in PEEP or FiO ₂
	$PEEP > 8 \text{ cm } H_2O$	Increase in FiO ₂
FiO ₂ >40%	$PEEP \le 8 \text{ cm } H_2O$	Increase in PEEP
	PEEP > 8 cm H_2O	Increase in FiO ₂

RM Procedure

Patients will be placed in SIMV-PC mode with a fixed driving pressure of 15 cm H₂O above PEEP. Respiratory rate (RR), inspiratory time (Ti), and FiO₂ will remain unchanged from baseline. Sequential RM will be performed, increasing PEEP by 5 cm H₂O every 2 minutes until a maximum PEEP of 20 cm H₂O. Then, PEEP will be decreased by 2 cm H₂O every 2 minutes when PEEP is >10 cm H₂O or by 1 cm H₂O every 2 minutes when PEEP is <10 cm H₂O. During the decremental phase of the maneuver, PEEP will be optimized to achieve better dynamic compliance (Cdyn) (decremental PEEP trial). Then, PEEP will be increased to 20 cm H₂O and maintained for 2 minutes. After RM, optimal PEEP will be set at the PEEP with the best Cdyn plus 2 cm H₂O, and the other parameters will be returned back to the previous level. Maneuvers will be manually performed using the Puritan Bennett[™] 840 Ventilator (Covidien, Medtronic Inc., Minneapolis, MN) (Figure 2). In our trial, RM will be performed by two respiratory therapists, one performing the procedure and the other monitoring the process.

Weaning from MV

All patients will follow the same analgesia and sedation protocols and treatment principles. Additionally, physicians will apply the same care interventions for general management of patients according to current guideline standards. Physicians will interrupt sedation once daily, and respiratory therapists will manage patients with the Spontaneous Breathing Trials (SBT) safety screen every morning. Patients who pass the SBT safety screen will undergo a 30-minute SBT with a pressure support ventilation of 5–7 cm H₂O, PEEP of 5 cm H₂O, and FiO₂ of \leq 40%. When the SBT safety screen is successful, physicians and respiratory therapists will extubate patients ^[21].

Management of nasal continuous positive airway pressure (NCPAP)

Patients considered high-risk for failed extubation will receive preventative NCPAP in the immediate post-extubation period. Risk factors for extubation failure are as follows: 1) decreased left ventricular systolic function; 2) refractory atelectasis; 3) O-shaped tracheal cartilage and airway stenosis caused by cardiac expansion; 4) >20% decrease in PaO₂ after SBT. Patients without these risk factors will receive conventional oxygen therapy, shifting to NIV if any of the following five indications appear: 1) mild-to-moderate dyspnea, retraction or accessory muscle use, grunting, nasal flaring, head bobbing; 2) abnormal outcomes on arterial blood gas analysis (pH < 7.35, PaCO₂ > 45 mmHg [1 mmHg = 0.133 kPa], or PaO₂/FiO₂ < 250 mmHg); 3) SpO₂ < 92% with supplemental O₂; 4) requiring an oxygen flow of >2 L/min; 5) tachypnea, RR of >50 breaths per min (<1 year old) or RR >40 breaths per min (1–4 years old) ^[22-24].

In the initial stage of NCPAP, patients will receive CPAP at 4–6 cm H_2O and a total flow of either 6–12 L/min (infants) or 8–20 L/min (pediatrics) depending on their age. CPAP, FiO₂, and total flow will be adjusted to achieve target oxygenation and ventilation goals, as described above. If SpO₂ is <92%,

CPAP will be increased by 1–2 cm H₂O (maximum, 10 cm H₂O) and FiO₂ by 0.05–0.10 per increment. For patients with a SpO₂ of >97%, FiO₂ will be decreased first by 0.05 per decrement until FiO₂ is <0.35. If SpO₂ is still >97%, CPAP will be decreased by 1 cm H_2O per decrement. When a CPAP of 2–3 cm H_2O combined with a FiO₂ <0.35 is sufficient to maintain target oxygenation and ventilation goals, patients will be switched to conventional oxygen therapy.

Indications for reintubation are as follows: 1) respiratory acidosis (pH < 7.35 and $PaCO_2 > 45$ mmHg, or an increase in PaCO₂ of >15% compared with pre-extubation level); 2) hypoxemia (FiO₂ > 50%, PaO₂ < 60 mmHg, or SpO₂ < 90%); 3) rapid RR as defined in Table 3; 4) respiratory fatigue and severe dyspnea; 5) inability to maintain the natural airway; 6) persistent respiratory acidosis, hypoxemia, dyspnea even on NCPAP/NIV^[25].

Patients with occurrence of the first indication, the second indication, or any other two indications will Zie be reintubated.

Table 3. Rapid RR based on ages

Age (years)	Respiratory rate (breaths per min)
<1	>60
1–2	>45
2–5	>40
>5	>35

Patient termination and withdrawal criteria

At any time, the next of kin can retreat patients from the study. Patients may be withdrawn from the study because of: (1)severe adverse events(barotrauma, arrhythmia and cardiac arrest); or (2) violating or

BMJ Open

deviating from the protocol; or (3) severe hypoxemia who meet the indication of ECMO or HFOV. If a patient is withdrawn for one of the three reasons mentioned, security analysis will be implemented.

Outcomes

The primary outcome is the duration of MV. The duration of MV refers to the time between admission to the ICU and extubation(hours). The secondary endpoints include PaO₂/FiO₂ (mmHg), respiratory system compliance, duration of non-invasive ventilation (from the initiation to the weaning ,hours), reintubation rate in 48 hours after extubation, length of ICU stay(from the admission the ICU to discharge from ICU, days), length of hospital stay(from the admission the hospital to discharge from hospital ,days), occurrence of serious adverse event(barotrauma, arrhythmia and cardiac arrest), postoperative pulmonary complications(respiratory infection, respiratory failure, pleural effusion, pneumothorax, atelectasis, bronchospasm, etc.). Before recruiting subjects, ventilator-free days through day 28 was added as a secondary outcome measure based on the lung recruitment studies in adults with ARDS and reviewers' opinions (If the patient dies before 28 days, ventilator-free days equals 0; If the patient is successfully weaned from mechanical ventilation within 28 days, ventilator-free days equals (28-x); If the patient requires mechanical ventilation for 28 days or more; ventilator-free days equals 0).

Sample size

The duration of mechanical ventilation following cardiac surgery vary substantially across hospitals.^[26] At the same time, no previous studies can be used as a reference.According to the information system data of health care before and after the implementation of RM in our PICU (2019 vs 2020), the average duration of mechanical ventilation in pediatrics after cardiac surgery was 16 hours and 11 hours, respectively. The study sample size was calculated on the basis of an expected 11 hours of MV in the lung recruitment group and 16 hours in the conventional group. Allowing for a 10% dropout rate, 117

patients are required for each group. After reviewing multiple adult lung recruitment studies, we conclude that the sample size of 234 cases will be sufficient^[5 27 28].

Randomization

Patients will be randomized in a 1:1 ratio to a conventional group or to a lung recruitment group. The random allocation list was generated by a statistician with no clinical involvement in the trial using a computer-generated random number list. Then the statistician will use sequentially numbered containers to implement the random allocation sequence, and the treatment allocation group will be hidden beyond the coated card in the container. For patients who meet the required criteria, the investigator will open a randomized card that records the treatment allocation group. Hence, treatment allocation will be r revie concealed.

Patient and Public Involvement

No patient and public involved.

Data collection and inspection

The principal investigators will centralize all data weekly and examine the accuracy of these data to promote data quality. Data collection for each patient will begin on the day that informed consent was received from the patient and will continue until the patient is discharged or transferred to another hospital. Data will be collected using a paper-based case report form (see Online Supplementary files 1-3) and an electronic database. Investigators will follow a schedule for data collection, including: (1) screening data, informed consent, demographic data, inclusion and exclusion criteria, and enrollment data; (2) baseline information (age, sex, ID, height, weight, diagnosis, type of surgery, pulmonary infection, airway stenosis, pulmonary hypertension, duration of cardiopulmonary bypass, Pediatric Risk of Mortality score, Risk Adjustment in Congenital Heart Surgery score(RACHS score), vasoactive-

inotropic score(VIS score), antibiotic therapy); (3) daily information on cardiovascular system (heart rate, blood pressure, central venous pressure, urine output, dosage of vasoactive agents), respiratory system (ventilator settings, PaO₂, PaCO₂, lung compliance), infection (white blood count, procalcitonin, C-reactive protein, interleukin-6), liver function (bilirubin, alanine aminotransferase, aspartate aminotransferase, albumin), renal function (urea nitrogen, creatinine); 4)prognosis: time of admission to ICU , extubation, initiation of NIV and reintubation , date of transferring out of the intensive care unit and date of discharge/death, whichever comes first.

Adverse events

RM related adverse events include transient hypotension (4weeks-1year SBP < 65mmHg, 1year-4years SBP < 70mmHg, 5years-12 years SBP < 80mmHg, >12 years SBP < 90mmHg), hypoxemia (SpO₂ < 84%) for more than 1 minute, and heart rate decreased or increased by more than 20% of the base value. RM won't be continued in those patients with adverse events and will be started again at another time. Severe adverse events include barotrauma (such as, pneumothorax, subcutaneous emphysema, mediastinal emphysema, interstitial emphysema), arrhythmias and cardiac arrest, etc. If severe adverse events happen, patient will be retreated from RM group. All patients who will receive RM will be monitored for blood pressure, SpO₂, and ECG, and will receive physical examination to assess barotrauma in real time. If necessary, lung ultrasound or chest imaging can be performed during or after the RM. Researchers will record and report adverse events and severe adverse events timely, at the same time, appropriate treatment for those adverse events will be prescribed to patients.

Data analysis

Descriptive statistics will be expressed as mean \pm SD or median and interquartile range depending on the nature and distribution of the variables. Inferential statistics will use estimates of the mean of the 13

differences and their 95 % confidence intervals (CI). Variables normally distributed will be compared with the Student's t test. For variables without a normal distribution, the Mann-Whitney U rank test will be used for comparison. Categorical variables will be compared using Fisher's exact test. The primary outcome variable (total duration of MV) and ventilator-free days through day 28 will be assessed with the Student's t test or the Mann-Whitney U rank test dependent on the distribution of the data. The relative risks and their 95 % CIs will be estimated. For all these comparisons, we will consider a difference to be statistically significant if p < 0.05.

Safety and quality control

 Recent studies have demonstrated the efficacy and safety of lung recruitment performed by incremental and decremental PEEP ^[8 10 11]. The study applicants and other primary investigators performed detailed and rigorous lung recruitment, which was applied to more than 200 patients at our pediatric ICU. Each patient demonstrated an increase in PaO₂, improved lung compliance, and a decrease in PaO₂, while none of them showed pneumothorax, subcutaneous emphysema, or other complications.

Ethics and dissemination

The protocol has been registered at the Chinese Clinical Trial registry (registration number: ChiCTR1900025990). Any revisions to the protocol will be documented in the ClinicalTrials.gov registry. Written informed consent has and will be obtained from all patients. All included patients will be able to access and correct the data. In the event of additional studies from the database, all investigators will keep the results confidential until publicly available, and they will not publish any data related to the database without approval of the principal investigator. We will publish the results of this trial in peer reviewed clinical journals and present the findings at conferences for widespread dissemination.

Acknowledgement

We would like to thank TopEdit (www.topeditsci.com) for English language editing of this manuscript.

Author Contributions

LJD and GPL together designed the study. ND and MMG drafted the manuscript. LJD and ND critically revised the manuscript. ND, MMG and WXX contributed to the study development. ND and MMG contributed equally to this paper.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-

profit sectors

Competing interests

None declared.

ation Patient consent for publication

Not required.

Ethics approval

The study has been approved by the ethics committee of West China Hospital, Sichuan University.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional unpublished data are available.

References

1.	Bartz RR, Ferreira RG, Schroder JN, et al. Prolonged pulmonary support after cardiac surgery:
	incidence, risk factors and outcomes: a retrospective cohort study. J Crit Care
	2015; 30 (5):940-44.
2.	Gajic O, Dabbagh O, Park PK, et al. Early Identification of Patients at Risk of Acute Lung
	Injury. <i>Am J Resp Crit Care Med</i> 2011; 183 (4):462-70.
3.	Lapinsky SE, Mehta S. Bench-to-bedside review: Recruitment and recruiting maneuvers. Crit
	<i>Care</i> 2005; 9 (1):60-5.
4.	Borges JB, Okamoto VN, Matos GF, et al. Reversibility of lung collapse and hypoxemia in
	early acute respiratory distress syndrome. Am J Respir Crit Care Med 2006;174(3):268-78.
5.	Goligher EC, Hodgson CL, Adhikari NKJ, et al. Lung Recruitment Maneuvers for Adult
	Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.
	Ann Am Thorac Soc 2017;14(Supplement_4):S304-S11.
6.	Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute
	respiratory distress syndrome. N Engl J Med 2006;354(17):1775–86.
7.	Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European
	Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice
	Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress
	Syndrome. <i>Am J Respir Crit Care Med</i> 2017; 195 (9):1253-63.
8.	Gernoth C, Wagner G, Pelosi P, et al. Respiratory and haemodynamic changes during
	decremental open lung positive end-expiratory pressure titration in patients with acute
	respiratory distress syndrome. Crit Care 2009;13(2):R59.

BMJ Open

9.	Boriosi JP, Cohen RA, Summers E, et al. Lung aeration changes after lung recruitment in
	children with acute lung injury: a feasibility study. <i>Pediatr Pulmonol</i> 2012;47(8):771-9.
10.	Boriosi JP, Sapru A, Hanson JH, et al. Efficacy and safety of lung recruitment in pediatric
	patients with acute lung injury. <i>Pediatr Crit Care Med</i> 2011; 12 (4):431-6.
11.	Duff JP, Rosychuk RJ, Joffe AR. The safety and efficacy of sustained inflations as a lung
	recruitment maneuver in pediatric intensive care unit patients. Intensive Care Med
	2007; 33 (10):1778-86.
12.	Halbertsma FJ, Vaneker M, Pickkers P, et al. A single recruitment maneuver in ventilated
	critically ill children can translocate pulmonary cytokines into the circulation. J Crit Care
	2010; 25 (1):10-15.
13.	Pediatric Acute Lung Injury Consensus Conference G. Pediatric acute respiratory distress
	syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus
	Conference. Pediatr Crit Care Med 2015;16(5):428-39.
14.	Tusman G, H. Böhm S, Tempra A, et al. Effects of recruitment maneuver on atelectasis in
	anesthetized children. Anesthesiology 2003;98(1):14-22.
15.	Jauncey-Cooke J, East CE, Bogossian F. Paediatric lung recruitment: a review of the clinical
	evidence. Paediatr Respir Rev 2015;16(2):127-32.
16.	Kheir JN, Walsh BK, Smallwood CD, et al. Comparison of 2 Lung Recruitment Strategies in
	Children With Acute Lung Injury. Respir Care 2012;58(8):1280-90.
17.	Cruces P, Donoso A, Valenzuela J, et al. Respiratory and hemodynamic effects of a stepwise
	lung recruitment maneuver in pediatric ARDS: a feasibility study. Pediatr Pulmonol
	2013; 48 (11):1135-43.
17	

18.	Marcus RJ, van der Walt JH, Pettifer RJA. Pulmonary volume recruitment restores pulmonary
	compliance and resistance in anaesthetized young children. Paediatr Anaesth 2002;12: 579-
	84.
19.	Wolf GK, Gomez-Laberge C, Kheir JN, et al. Reversal of dependent lung collapse predicts
	response to lung recruitment in children with early acute lung injury. Pediatr Crit Care Med
	2012; 13 (5):509-15.
20.	Kneyber MCJ, de Luca D, Calderini E, et al. Recommendations for mechanical ventilation of
	critically ill children from the Paediatric Mechanical Ventilation Consensus Conference
	(PEMVECC). Intensive Care Med 2017;43(12):1764-80.
21.	Schmidt GA, Girard TD, Kress JP, et al. Liberation From Mechanical Ventilation in Critically
	Ill Adults: Executive Summary of an Official American College of Chest
	Physicians/American Thoracic Society Clinical Practice Guideline. Chest 2017;151(1):160-
	65.
22.	Oymar K, Bardsen K. Continuous positive airway pressure for bronchiolitis in a general
	paediatric ward; a feasibility study. BMC Pediatr 2014;14:122.
23.	Wilson PT, Morris MC, Biagas KV, et al. A randomized clinical trial evaluating nasal
	continuous positive airway pressure for acute respiratory distress in a developing country. J
	<i>Pediatr</i> 2013; 162 (5):988-92.
24.	Mayordomo-Colunga J, Medina A, Rey C, et al. Non invasive ventilation after extubation in
	paediatric patients: a preliminary study. BMC Pediatr 2010;10:29.

25.	Stucki P, Perez MH, Scalfaro P, et al. Feasibility of non-invasive pressure support ventilation
	in infants with respiratory failure after extubation a pilot study. Intensive Care Med
	2009; 35 (9):1623-27.
26.	Gupta P, Tang X, Gossett JM, et al. Variation of Ventilation Practices With Center Volume
	After Pediatric Heart Surgery. Clin. Cardiol 2015;38(3):178-84.
27.	Eronia N, Mauri T, Maffezzini E, et al. Bedside selection of positive end-expiratory pressure
	by electrical impedance tomography in hypoxemic patients: a feasibility study. Ann Intensive
	<i>Care</i> 2017; 7 (1):76.
28.	Kung SC, Hung YL, Chen WL, et al. Effects of Stepwise Lung Recruitment Maneuvers in
	Patients with Early Acute Respiratory Distress Syndrome: A Prospective, Randomized,
	Controlled Trial. J Clin Med 2019;8(2).
Figure 1	. Enrollment and Study Protocol.
Figure 2	2. Recruitment maneuver (RM) procedure. The RM will be performed in synchronized
intermit	tent mandatory ventilation-pressure control (SIMV-PC) mode with a fixed driving pressure (DP)
of 15 cn	nH_2O above positive end-expiratory pressure (PEEP). PEEP will be increased by 5 cmH ₂ O
every 2	minutes to a maximum of 25 cm H_2O . During the decremental phase of the RM, PEEP will be

optimized to achieve better dynamic compliance (Cdyn; decremental PEEP trial). The PEEP with the best Cdyn is called the closing pressure. After the decremental PEEP trial, the RM will be repeated

with a PEEP of 20 cmH₂O and a DP of 15 cmH₂O. The optimal PEEP will be the closing pressure plus

2 cmH₂O. For example, Figure 2 shows that the PEEP with the best Cdyn is 9 cmH₂O. Thus, PEEP will be set to 11 cmH₂O.

For peer review only




Figure 1 Enrollment and Study Protocol




Figure 2. Recruitment maneuver (RM) procedure. The RM will be performed in synchronized intermittent mandatory ventilation-pressure control (SIMV-PC)mode with a fixed driving pressure (DP) of 15 cmH₂O above positive end-expiratory pressure (PEEP). PEEP will be increased by 5 cmH₂O every 2 minutes to a maximum of 25 cmH₂O. During the decremental phase of the RM, PEEP will be optimized to achieve better dynamic compliance (Cdyn; decremental PEEP trial). The PEEP with the best Cdyn is called the closing pressure. After the decremental PEEP trial, the RM will be repeated with a PEEP of 20 cmH₂O and a DP of 15 cmH₂O. The optimal PEEP will be the closing pressure plus 2 cmH₂O. For example, Figure 2 shows that the PEEP with the best Cdyn is 9 cmH₂O. Thus, PEEP will be set to 11 cmH₂O.

patient ID	age	sex	male femal
body weight	kg height	cm_ethnic	
Preoperative data			
diagnosis			
pulmonary infec ye	es no pulmonary a	□yes (mild /moderate	/s□no
airway stenosis ye	es□ no□		
difficulty airway ye	es□ no□		
Operative data			
operative route m	iddle incisiclateral incisior	םו	
bypass time, mins			
Circulatory arres ye	es no		
Use of bloodpro ye			
postoperative P/F(
			_
ICU Admission			
time		surgery	
diagnosis		<u> </u>	
PRISM score	RACHS score		
VIS score in 24 h	ours	$3 \times epipephrine + 10 \times m$	ulrinone + 10 00
VIS score in 24 he (VIS score= dopa	ours amine + dobutamine + 100	0 × epinephrine + 10 × m	nilrinone + 10 00
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)	0 × epinephrine + 10 × m	nilrinone + 10 00
VIS score in 24 he (VIS score= dopa	ours amine + dobutamine + 100 onepinephrine)	0 × epinephrine + 10 × m	nilrinone + 10 00
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)	0 × epinephrine + 10 × m	nilrinone + 10 00
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)	0 × epinephrine + 10 × m	nilrinone + 10 00
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		hilrinone + 10 00
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		
VIS score in 24 <u>h</u> (VIS score= dopa Pituitrin+ 100 × no	ours amine + dobutamine + 100 onepinephrine)		

Patient demograph	ics		
patient ID		sex	male female
body weight	age kg height	sex cm ethnic	
body weight			
Preoperative data			
diagnosis		_	
pulmonary infec yes	non pulmonary a	u⊐yes (mild /moderate	/s □no
airway stenosis yes	s⊡ no⊡		
difficulty airway yes	i⊡ no□		
Operative data			
-	ddle incisiclateral incisio	n⊓	
bypass time, mins			
Circulatory arres yes	no no		
Use of bloodpro yes		-	
postoperative P/F(n		-	
		·	
ICU Admission			
time		surgery	
diagnosis			
PRISM score	RACHS score	· /	
(VIS score in $\overline{24}$ I			
•	•	$0.0 \times opinophring + 10 \times 10$	milringna i 10.000
		00 × epinephrine + 10 × i	minnone + 10 000
Pituitrin+ 100 × nor	iepinephrine)		
lowest P/F ,mm <u>Hg</u>			
	For peer review only - http:/	//bmjopen.bmj.com/site/abc	out/guidelines.xhtml

1 2		D0	D1	D2	D3	D4
2 3	Date	50			05	
4	Circulatory system					
5	HRg beat/minh					
6 7	-					
8	BPg mmHgh					
9	mean BPgmmHg h					
10	CVPg mmHgh					
11 12	fluid inputg mlh					
13	fluid output g mlh					
14						
15	dopamine µg/ kg·minh					
16 17	milrinone µg/ kg·minh					
18	epinephrine μg/ kg·mir	h o				
19	nonepinephrine µg/ kg	·r				
20 21	pituitrinµg/ kg∙minh					
21	Respiratory system					
23	ventilation mode					
24	fg /minh					
25 26	Pig cmH ₂ Oh					
27	PEEPg cmH ₂ Oh					
28	FiO ₂					
29 30	PaO ₂					
31	PaO_2/FiO_2					
32	SaO ₂					
33 34	Laboratory examination					
35	ABG					
36	рН					
37 38	PaO ₂ g mmHgh					
39	PaCO ₂ g mmHgh					
40						
41 42	BE					
42	HCO ₃ g mmHgh					
44	Lacg mmol/Lh					
45 46	Infectious index					
46 47	WBCg X10 ⁹ h					
48	РСТ					
49 50	CRP					
50 51						
52	Liver function					
53	bilirubin					
54 55	ALT					
55 56	AST					
57	ALBg g/Lh					
58						
59 60	For pe	er review only -	http://bmiopen	.bmi.com/site/a	bout/auidelines	xhtml

Renal function										
BUN										
CREAg umol/Lh										
Blood routine examinatio	n									
Plt										
Hbg g/Lh										
	D0		D1		D2		D3		D4	
date	-						-			
Etiological data										
positive sputum culture	ves□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	nc
pathogen			,		,		,		,	
Respiratory virus test										
influenza a virus	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	nc
adenovirus	, yes□		yes□		yes□		, yes□		yes□	
Bocavirus	yes□	no□	yes 🗆	no□	yes□	no□	yes□	no□	yes□	
rhinovirus	yes□	no□	yes□	no□	yes□		yes□	no□	yes□	
H1N1	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	nc
Parainfluenza viru	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	nc
chlamydia	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	nc
Human metapneumovirus	yes□	no□	yes□	no	yes□	no□	yes□	no□	yes□	nc
influenza B virus	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
Mycoplasma pneumoniae	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
H3N2	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
coronavirus	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
respiratory syncytial virus	yes□	no□	yes□	no□	yes□	noロ	yes□	no□	yes□	nc
TORCH			yes□	no□						
tomegalovirus antibody Ig	5		yes□	no□						
Rubella virus antibody IgM			yes□	no□						
lex virus antibody type I/II			yes□	no□						
oplasma antibody(Tox-Ab)			yes□	no□						
Imaging finding										
new or progressive infiltra	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	nc
Body temperature $(^{\circ}C)$										
highest body temperature										
lowest body temperature										
							bout/gu			

1		D5	D6	D7	D8	D9
2 3	Data	60			Do	50
4	Date					
5	Circulatory system					
6	HRg beat/minh					
7	BPg mmHgh					
8 9	mean BPgmmHg h					
10	CVPg mmHgh					
11	fluid inputg mlh					
12	fluid output g mlh					
13 14						
14	dopamine µg/ kg·minh					
16	milrinone µg/ kg·minh					
17		h				
18	nonepinephrine µg/ kg	.r 🔾				
19 20	pituitrinµg/ kg·minh					
21	Respiratory system	in •r				
22	ventilation mode					
23						
24 25	fg /minh					
26	Pig cmH ₂ Oh					
27	PEEPg cmH ₂ Oh					
28 29	FiO ₂					
29 30	PaO ₂					
31	PaO_2/FiO_2					
32	SaO ₂					
33 34	Jaboratory ovamination					
35	Laboratory examination					
36	ABG					
37	pH					
38 39						
40	PaCO ₂ g mmHgh					
41	BE					
42	HCO ₃ g mmHgh					
43 44	Lacg mmol/Lh					
45	Infectious index					
46	WBCg X10 ⁹ h					
47	PCT					
48 49	CRP					
50	en					
51	Liver function					
52	Liver function					
53 54	bilirubin					
55	ALT					
56	AST					
57	ALBg g/Lh					
58 59						
59 60	For pe	er review only -	http://bmiopen	.bmi.com/site/a	bout/auidelines	sxhtml

Renal function					
BUN					
CREAg umol/Lh					
Blood routine examinatio	n				
Plt					
Hbg g/Lh					
	D5	D6	D7	D8	D9
date	65	DU	U/	20	65
Etiological data					
positive sputum culture	yes□ no□	yes□ no□	yes□ no□	yes□ no□	yes□ no□
pathogen	,coll noll	,002 1102	,002 1102	,002 1102	,002 1102
Respiratory virus test					
influenza a virus	yes□ no□	yes□ no□	yes□ no□	yes□ no□	yes□ no□
adenovirus	, yes□ no□	, yes□ no□	, yes□ no□	, yes□ no□	, yes□ no□
Bocavirus	, yes□ no□	yes□ no□	, yes□ no□	, yes□ no□	, yes□ no□
rhinovirus	yes no	yes□ no□	, yes□ no□	, yes□ no□	, yes□ no□
H1N1	yes□ no□	yes□ no□	yes□ no□	, yes□ no□	yes□ no□
Parainfluenza viru	yes□ no□	yes□ no□	, yes□ no□	, yes□ no□	yes□ no□
chlamydia	yes□ no□	yes no	yes□ no□	yes□ no□	yes□ no□
Human metapneumovirus	syes⊡ no⊡	yes□ no□	yes□ no□	yes□ no□	yes□ no□
influenza B virus	yes□ no□	yes□ no□	yes□ no□	yes□ no□	yes□ no□
Mycoplasma pneumoniae	yes□ no□	yes□ no□	yes□ no□	yes□ no□	yes□ no□
H3N2	yes□ no□	yes□ no□	yes□ no□	yes□ no□	yes□ no□
coronavirus	yes□ no□	yes□ no□	yes□ no□	yes□ no□	yes□ no□
respiratory syncytial virus	yes□ no□	yes□ no□	yes□ no□	yes□ no□	yes□ no□
TORCH		yes□ no□			
tomegalovirus antibody Ig	5				
Rubella virus antibody IgN					
lex virus antibody type I/II					
oplasma antibody(Tox-Ab)					
Imaging finding					
new or progressive infiltr	ayes⊡ no⊡	yes□ no□	yes□ no□	yes□ no□	yes□ no□
Body temperature ($^{\circ}$ C)					
highest body temperature					
lowest body temperature	£				
For pee	r review only - h	ttp://bmjopen.b	omj.com/site/ab	out/guidelines.>	khtml

BMJ Open

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to

include the missing information. If you are certain that an item does not apply, please write "n/a" and

provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A,

Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D, SPIRIT 2013 Explanation and

Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Page Reporting Item Number **Administrative** information Title #1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 30 of 38

1 2	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered,	3
3 4 5			name of intended registry	
6 7	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	3
8 9 10 11	data set		Registration Data Set	
12 13 14	Protocol version	<u>#3</u>	Date and version identifier	3
15 16 17 18 19	Funding	<u>#4</u>	Sources and types of financial, material, and other support	15
20 21	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	1,15
22 23 24	responsibilities:			
25 26 27	contributorship			
28 29	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	N/A no
30 31	responsibilities:			funding
32 33 34	sponsor contact			
34 35 36 37	information			
38 39	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study	N/A no
40 41	responsibilities:		design; collection, management, analysis, and	funding
42 43	sponsor and funder		interpretation of data; writing of the report; and the	
44 45 46			decision to submit the report for publication, including	
40 47 48			whether they will have ultimate authority over any of	
49 50 51			these activities	
52 53 54	Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the	N/A no
54 55 56	responsibilities:		coordinating centre, steering committee, endpoint	funding
57 58	committees		adjudication committee, data management team, and	
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 31 d	of 38
-----------	-------

5				
1			other individuals or groups overseeing the trial, if	
2 3			applicable (see Item 21a for data monitoring	
4 5 6			committee)	
7 8	Introduction			
9 10				
11 12	Background and	<u>#6a</u>	Description of research question and justification for	5
13 14	rationale		undertaking the trial, including summary of relevant	
15 16			studies (published and unpublished) examining	
17 18 19			benefits and harms for each intervention	
20				_
21 22	Background and	<u>#6b</u>	Explanation for choice of comparators	5
23 24	rationale: choice of			
25 26 27	comparators			
28 29	Objectives	#7	Specific objectives or hypotheses	5
30 31		<u></u>		Ū
32 33	Trial design	<u>#8</u>	Description of trial design including type of trial (eg,	6
34 35			parallel group, crossover, factorial, single group),	
36 37			allocation ratio, and framework (eg, superiority,	
38 39			equivalence, non-inferiority, exploratory)	
40 41	Methods:			
42 43				
44 45 46	Participants,			
47 48	interventions, and			
49 50	outcomes			
51 52	Study setting	<u>#9</u>	Description of study settings (eg, community clinic,	6
53 54			academic hospital) and list of countries where data will	
55 56			be collected. Reference to where list of study sites can	
57 58 59				
60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			be obtained	
3 4	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If	6
5 6 7			applicable, eligibility criteria for study centres and	
, 8 9			individuals who will perform the interventions (eg,	
10 11 12			surgeons, psychotherapists)	
13 14	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to	7-8
15 16 17	description		allow replication, including how and when they will be	
18 19 20			administered	
21 22	Interventions:	<u>#11b</u>	Criteria for discontinuing or modifying allocated	10-11
23 24	modifications		interventions for a given trial participant (eg, drug dose	
25 26			change in response to harms, participant request, or	
27 28 29 30			improving / worsening disease)	
31 32	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention	8
33 34	adherance		protocols, and any procedures for monitoring	
35 36 37			adherence (eg, drug tablet return; laboratory tests)	
38 39 40	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that are	7-11
40 41 42 43	concomitant care		permitted or prohibited during the trial	
44 45	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the	11
46 47			specific measurement variable (eg, systolic blood	
48 49			pressure), analysis metric (eg, change from baseline,	
50 51 52			final value, time to event), method of aggregation (eg,	
53 54			median, proportion), and time point for each outcome.	
55 56			Explanation of the clinical relevance of chosen efficacy	
57 58			and harm outcomes is strongly recommended	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including	5
3 4			any run-ins and washouts), assessments, and visits for	
5 6 7			participants. A schematic diagram is highly	
7 8 9 10			recommended (see Figure)	
10 11 12	Sample size	<u>#14</u>	Estimated number of participants needed to achieve	11-12
13 14			study objectives and how it was determined, including	
15 16			clinical and statistical assumptions supporting any	
17 18 19 20			sample size calculations	
20 21 22	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment	11-12
23 24 25			to reach target sample size	
26 27	Methods:			
28 29 30	Assignment of			
31 32	interventions (for			
22				
33 34 35	controlled trials)			
34 35 36 37		<u>#16a</u>	Method of generating the allocation sequence (eg,	12
34 35 36 37 38 39		<u>#16a</u>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any	12
34 35 36 37 38 39 40 41	Allocation: sequence	<u>#16a</u>		12
34 35 36 37 38 39 40	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 	Allocation: sequence generation		computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 	Allocation: sequence generation Allocation		computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions Mechanism of implementing the allocation sequence	

1 2			sequence until interventions are assigned	
3 4 5	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will	12
6 7	implementation		enrol participants, and who will assign participants to	
, 8 9 10			interventions	
11 12	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions	12
13 14			(eg, trial participants, care providers, outcome	
15 16 17 18			assessors, data analysts), and how	
19 20	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	N/A, always
21 22	emergency		permissible, and procedure for revealing a participant's	be blinded
23 24	unblinding		allocated intervention during the trial	
25 26 27 28	Methods: Data			
29 30	collection,			
31 32	management, and			
33 34	analysis			
35 36 37 38	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome,	12-13
39 40			baseline, and other trial data, including any related	
41 42			processes to promote data quality (eg, duplicate	
43 44			measurements, training of assessors) and a	
45 46			description of study instruments (eg, questionnaires,	
47 48 49			laboratory tests) along with their reliability and validity,	
50 51			if known. Reference to where data collection forms can	
52 53 54			be found, if not in the protocol	
55 56	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete	12-13
57 58	retention		follow-up, including list of any outcome data to be	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 35 of 38

1 2			collected for participants who discontinue or deviate	
3 4 5			from intervention protocols	
6 7	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage,	12-13
8 9			including any related processes to promote data quality	
10 11			(eg, double data entry; range checks for data values).	
12 13			Reference to where details of data management	
14 15 16			procedures can be found, if not in the protocol	
17 18	Statistics: outcomes	#20a	Statistical methods for analysing primary and	13-14
19 20			secondary outcomes. Reference to where other details	-
21 22 23			of the statistical analysis plan can be found, if not in the	
23 24 25			protocol	
26 27				
28 29	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and	N/A no
30 31	analyses		adjusted analyses)	subgroup
32 33 34				analyses
35 36	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol	N/A
37 38	population and		non-adherence (eg, as randomised analysis), and any	
39 40 41	missing data		statistical methods to handle missing data (eg, multiple	
42 43			imputation)	
44 45	Mathada: Manitaring			
46 47	Methods: Monitoring			
48 49	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC);	14
50 51				
51	formal committee		summary of its role and reporting structure; statement	
	formal committee		summary of its role and reporting structure; statement of whether it is independent from the sponsor and	
51 52 53 54 55 56	formal committee			
51 52 53 54 55 56 57 58	formal committee		of whether it is independent from the sponsor and	
51 52 53 54 55 56 57		or peer re	of whether it is independent from the sponsor and competing interests; and reference to where further	

1			protocol. Alternatively, an explanation of why a DMC is	
2 3			not needed	
4 5				
6 7 8 9	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping	N/A No
	interim analysis		guidelines, including who will have access to these	interim
10 11			interim results and make the final decision to terminate	results
12 13 14			the trial	
15 16	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and	13
17 18 19			managing solicited and spontaneously reported	
20 21			adverse events and other unintended effects of trial	
22 23			interventions or trial conduct	
24 25	A 1977			
26 27	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if	N/A
28 29			any, and whether the process will be independent from	
30 31 32			investigators and the sponsor	
33 34	Ethics and			
35 36	dissemination			
37 38	D			
39 40	Research ethics <u>#24</u>		Plans for seeking research ethics committee /	14
41 42	approval		institutional review board (REC / IRB) approval	
43 44 45	Protocol	<u>#25</u>	Plans for communicating important protocol	14
46 47	amendments		modifications (eg, changes to eligibility criteria,	
48 49			outcomes, analyses) to relevant parties (eg,	
50 51 52			investigators, REC / IRBs, trial participants, trial	
52 53 54			registries, journals, regulators)	
55 56 57 58	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from	14
59 60		eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		

1 2 3 4			potential trial participants or authorised surrogates, and how (see Item 32)	
$\begin{array}{c} F \\ $	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	15
	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	15
	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 38 of 38

1 2	Dissemination policy:	<u>#31b</u>	Authorship eligibility guidelines and any intended use	15			
3 4 5	authorship		of professional writers				
6 7 8	Dissemination policy:	<u>#31c</u>	Plans, if any, for granting public access to the full	15			
9 10	reproducible		protocol, participant-level dataset, and statistical code				
11 12 13	research						
14 15 16	Appendices						
17 18	Informed consent	<u>#32</u>	Model consent form and other related documentation	Appendices			
19 20 21	materials		given to participants and authorised surrogates				
22 23	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage	N/A			
24 25 26			of biological specimens for genetic or molecular				
27 28			analysis in the current trial and for future use in				
29 30			ancillary studies, if applicable				
31 32							
33 34	None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution						
35 36	License CC-BY-ND 3.0. This checklist can be completed online using <u>https://www.goodreports.org/</u> , a						
37 38	tool made by the EQU	ATOR	Network in collaboration with Penelope.ai				
39 40							
41 42							
43 44							
45 46							
47							
48 49							
50 51							
52							
53 54							
55							
56 57							
58 59							
אר	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml						

BMJ Open

Study protocol for a single-center randomized controlled trial to investigate the effect of lung recruitment in pediatric patients after cardiac surgery

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063278.R1
Article Type:	Protocol
Date Submitted by the Author:	01-Apr-2022
Complete List of Authors:	Gu, Miaomiao; Sichuan University West China Hospital Deng, Ni; Sichuan University West China Hospital Xia, Wenxi; Sichuan University West China Hospital Deng, Lijing; Sichuan University West China Hospital, Department of Critical Care Medicine Liang, Guopeng; Sichuan University West China Hospital
Primary Subject Heading :	Paediatrics
Secondary Subject Heading:	Surgery, Intensive care
Keywords:	Cardiac surgery < SURGERY, Paediatric intensive & critical care < ANAESTHETICS, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Paediatric intensive & critical care < INTENSIVE & CRITICAL CARE, Paediatric intensive & critical care < PAEDIATRICS, Paediatric cardiac surgery < PAEDIATRIC SURGERY

SCHOLARONE[™] Manuscripts

2	
3	
4	Study protocol for a single-center randomized controlled trial to investigate the
5	
6	
7	effect of lung recruitment in pediatric patients after cardiac surgery
8	
9	
	Miaomiao Gu ¹ , Ni Deng ¹ , Wenxi Xia, Lijing Deng*, Guopeng Liang*
10	
11	Minutine Composition of Coldinal Composition West Object Herrital of Statement
12	Miaomiao Gu Department of Critical Care Medicine, West China Hospital of Sichuan
13	
14	University,Chengdu, China
15	omversity;onenguu; onnu
16	
17	Ni Deng Department of Critical Care Medicine, West China Hospital of Sichuan
18	
19	
20	University,Chengdu, China
21	
22	
	Wenxi Xia Department of Critical Care Medicine, West China Hospital of Sichuan
23	
24	University Changdy Chine
25	University,Chengdu, China
26	
27	Lijing Deng Department of Critical Care Medicine, West China Hospital of Sichuan
28	Lijing Deng Department of Critical Care intertence, west China Hospital of Stendard
29	
30	University,Chengdu, China
31	
32	
33	Guopeng Liang Department of Critical Care Medicine, West China Hospital of Sichuan
34	
35	
36	University,Chengdu, China
37	¹ Both authors contributed equally to this paper
38	Both authors contributed equany to this paper
39	
40	* Both corresponding authors contributed equally to this paper
41	
42	
43	
44	
45	
46	Correspondence to Dr Lijing Deng dengni-2004@163.com
47	
48	Dr Guopeng Liang liangguopeng007@163.com
49	Di Guopeng Liang hangguopengoo/@105.com
50	
51	Key words: pediatric, lung recruitment, cardiac surgery, hypoxemic respiratory failure
52	
53	
54	
55	
56	I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work
57	
58	(as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for
59	(as uchned in the below author needed), an exclusive needed and/or a non-exclusive needed for

contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Abstract

Introduction

A number of published studies have revealed that lung recruitment can improve oxygenation, shorten the duration of mechanical ventilation (MV), and decrease mortality in adults with acute hypoxemic respiratory failure, especially patients with acute respiratory distress syndrome. However, few articles have assessed lung recruitment in pediatric patients, especially after cardiac surgery. This clinical trial aimed to determine whether lung recruitment can reduce the duration of MV in pediatric patients with hypoxemic respiratory failure after cardiac surgery.

Method and analysis

In this trial, we will randomly assign 234 pediatric patients (aged 28 days to 14 years) within 72 hours after cardiac surgery with an arterial oxygen tension (PaO₂) to fraction of inspired oxygen (FiO₂) ratio (PaO₂/FiO₂) of \leq 300 to either a lung recruitment group or a conventional group. The primary endpoint will be the duration of MV. The secondary endpoints will be ventilator-free days, PaO₂/FiO₂, respiratory system compliance, duration of non-invasive ventilation, reintubation rate, length of ICU stay, length of hospital stay, occurrence of serious adverse events (barotrauma, persistent hypotension and arrhythmia), postoperative pulmonary complications.

Ethics and dissemination

The ethics committee of West China Hospital of Sichuan University granted ethics approval for this study (20/8/2019). The results will be published in peer-reviewed journals and presented at conferences.

Trial registration number: ChiCTR1900025990

Strengths and limitations of this study:

1. The protocol will be a randomized controlled trial, so the reliability of the results will be very high.

2. The incidence of hypoxic respiratory failure in pediatrics with congenital heart disease after surgery

is low, and it will take a long time to achieve the expected sample size.

3. Because of lack of sufficient research data on lung recruitment in pediatrics, we do not know whether

the methods, parameters of RM and the indications of repeat RM are reasonable, which may affect the

outcome of patients.

Introduction

Hypoxemic respiratory failure, especially acute respiratory distress syndrome (ARDS) after cardiac surgery, is the main cause of prolonged mechanical ventilation (MV). General anesthesia, extracorporeal circulation, procedure-related lung injury, and inappropriate ventilation strategies are risk factors for hypoxemic respiratory failure in patients after cardiac surgery ^[1]. A recent prospective multi-center study diagnosed 10% of patients with ARDS after cardiac surgery ^[2]. Compared with adults, pediatric patients are more likely to suffer from hypoxemic respiratory failure after cardiac surgery ^[2].

Lung recruitment maneuvers(RM) can prevent alveolar collapse, improve oxygenation, and enhance respiratory system compliance by temporarily increasing transpulmonary pressure ^[3]. Over the past two decades, a number of studies have confirmed the effectiveness of lung recruitment for improving oxygenation, reducing the duration of MV, and decreasing mortality in adults with hypoxemic respiratory failure, especially those diagnosed with ARDS ^[4-8]. However, studies investigating the clinical use of lung recruitment in pediatric patients are limited. Although several studies have reported that lung recruitment maneuvers combined with positive end-expiratory pressure (PEEP) titration can improve oxygenation and decrease the partial pressure of carbon dioxide in arterial blood (PaCO₂) in pediatric patients with hypoxemic respiratory failure, no studies have assessed the effectiveness of lung recruitment in reducing the duration of MV in pediatric patients after cardiac surgery ^[9-19].

As a result, this single-center study was designed to determine whether lung recruitment maneuvers combined with PEEP titration can reduce the duration of MV and intensive care unit (ICU) stay, as well as all-cause mortality rate, in pediatric patients after cardiac surgery.

Methods

Study setting

This study adopted a prospective, single-center, parallel group, randomized, controlled design and is ongoing at West China Hospital of Sichuan University (January 2020 to December 2022). The ethics committee of West China Hospital of Sichuan University granted ethics approval (20/8/2019).

Eligibility criteria

The inclusion criteria are as follows: 1) pediatric patients after cardiac surgery whose cardiac anatomical deficiency was completely corrected after surgery; 2) pediatric patients aged 28 days to 14 years; 3) partial pressure of oxygen (PaO₂) to fraction of inspired oxygen (FiO₂) ratio (PaO₂/FiO₂) of <300 with PEEP \geq 5cm H₂O within 72 hours after surgery.

The exclusion criteria are as follows: 1) pediatric patients deemed unsuitable for lung recruitment by the attending intensivist; 2) presence of an uncuffed endotracheal tube; 3) pneumothorax; 4) severe hemodynamic instability (requiring norepinephrine >0.2 μ g/kg/min or epinephrine >0.2 μ g/kg/min); 5) lack of consent from the next of kin; 6) diaphragmatic paralysis; 7) central nervous system complications; 8) raised intracranial pressure (>20 mmHg); 9) bronchopleural fistula;10)intracardiac shunt.

Participant selection and recruitment

Before identifying and screening patients for eligibility, all patients will be initially ventilated with synchronized intermittent mandatory ventilation-pressure control (SIMV-PC) using a Puritan BennettTM 840 Ventilator (Covidien, Medtronic Inc., Minneapolis, MN) for 30 minutes (Figure 1). Then the first arterial blood gas analysis will be obtained. Specific ventilator settings are described in Table 1. PetCO₂, an index of PaCO₂, will be monitored using a carbon dioxide (CO₂) analyzer. Informed consent will be obtained by the doctor in charge. All information will be transferred into an electronic database so that the trial office can monitor recruitment and refusal rates.

Age	Mode	F	Ti	Pi	Ps	FiO ₂	PEEP	vsens
4 weeks $<$ age \le 1 year	SIMV-PC	30	0.67	12	10	50%	5	1
1 year $<$ age \le 3 years	SIMV-PC	25	0.80	12	10	50%	5	1
3 years $<$ age \le 12 years	SIMV-PC	20	0.86	12	10	50%	5	1
Age > 12 years	SIMV-PC	15	1.0	12	10	50%	5	1

Table 1. Ventilator mode and initial settings.

Intervention

The intervention group comprises patients who have undergone lung recruitment and PEEP titration. The control group comprises patients who have undergone conventional MV. Patients will be prospectively followed from the day of enrollment for at least 28 days or until discharge, whichever comes first.

In both groups, the ventilation and oxygenation goals are as follows: 1) arterial pH, 7.35–7.45; PaCO₂, 35-45 mm Hg; 2) SpO₂, 92%-97% for patients with a PEEP <10 cm H₂O and 88%-92% for patients with a PEEP >10 cm H₂O. To prevent ventilator-induced lung injury, the general principle of ventilator setting includes limiting driving pressure to 15cm H₂O, plateau pressure to 28cm H₂O (allowing for slightly higher plateau pressures (29–32 cm H₂O) for patients with increased chest wall elastance), PEEP to 20 cm H₂O. In patients with severe hypoxemia, FiO₂ can be more than 60%.^[20] High-frequency oscillatory ventilation (HFOV) should be considered as an alternative ventilatory mode in patients in whom plateau airway pressures exceed 28 cm H₂O in the absence of clinical evidence of reduced chest wall compliance. ECMO may be considered in patients whose ventilation parameters have been maximized but still cannot achieve adequate gas exchange.^[13]

In the conventional group, PEEP and FiO_2 will be adjusted according to the PEEP-FiO₂ table (Table 2) to achieve the target SpO₂ described above. In the lung recruitment group, RM and decremental PEEP

titration will be performed immediately after enrollment and applied at least twice a day until extubation. RM will also be repeated if patients meet any of the following three conditions: 1) $PaO_2 \le 60 \text{ mmHg}$; 2) $SpO_2 \le 88\%$; 3) $PaCO_2 > 45 \text{ mmHg}$. Additionally, physicians will apply routine care interventions for the general management of critically ill patients, according to current guideline standards.

EO	DEED

Table 2. PEEP-FiO₂ table

FiO ₂	РЕЕР	Adjustment
$FiO_2 \leq 40\%$	$PEEP \le 8 \text{ cm } H_2O$	Increase in PEEP or FiO ₂
	PEEP > 8 cm H_2O	Increase in FiO ₂
FiO ₂ >40%	$PEEP \le 8 \text{ cm } H_2O$	Increase in PEEP
	PEEP > 8 cm H_2O	Increase in FiO ₂

RM Procedure

 Patients will be placed in SIMV-PC mode with a fixed driving pressure of 15 cm H₂O above PEEP. Respiratory rate (RR), inspiratory time (Ti), and FiO₂ will remain unchanged from baseline. Sequential RM will be performed, increasing PEEP by 5 cm H₂O every 2 minutes until a maximum PEEP of 20 cm H₂O. Then, PEEP will be decreased by 2 cm H₂O every 2 minutes when PEEP is >10 cm H₂O or by 1 cm H₂O every 2 minutes when PEEP is <10 cm H₂O. During the decremental phase of the maneuver, PEEP will be optimized to achieve better dynamic compliance (Cdyn) (decremental PEEP trial). Then, PEEP will be increased to 20 cm H₂O and maintained for 2 minutes. After RM, optimal PEEP will be set at the PEEP with the best Cdyn plus 2 cm H₂O, and the other parameters will be returned back to the previous level. Maneuvers will be manually performed using the Puritan Bennett[™] 840 Ventilator (Covidien, Medtronic Inc., Minneapolis, MN) (Figure 2). In our trial, RM will be performed by two respiratory therapists, one performing the procedure and the other monitoring the process.

Weaning from MV

All patients will follow the same analgesia and sedation protocols and treatment principles. Additionally, physicians will apply the same care interventions for general management of patients according to current guideline standards. Physicians will interrupt sedation once daily, and respiratory therapists will manage patients with the Spontaneous Breathing Trials (SBT) safety screen every morning. Patients who pass the SBT safety screen will undergo a 30-minute SBT with a pressure support ventilation of 5–7 cm H₂O, PEEP of 5 cm H₂O, and FiO₂ of \leq 40%. When the SBT safety screen is successful, physicians and respiratory therapists will extubate patients ^[21].

Management of nasal continuous positive airway pressure (NCPAP)

Patients considered high-risk for failed extubation will receive preventative NCPAP in the immediate post-extubation period. Risk factors for extubation failure are as follows: 1) decreased left ventricular systolic function; 2) refractory atelectasis; 3) O-shaped tracheal cartilage and airway stenosis caused by cardiac expansion; 4) >20% decrease in PaO₂ after SBT. Patients without these risk factors will receive conventional oxygen therapy, shifting to NIV if any of the following five indications appear: 1) mild-to-moderate dyspnea, retraction or accessory muscle use, grunting, nasal flaring, head bobbing; 2) abnormal outcomes on arterial blood gas analysis (pH < 7.35, PaCO₂ > 45 mmHg [1 mmHg = 0.133 kPa], or PaO₂/FiO₂ < 250 mmHg); 3) SpO₂ < 92% with supplemental O₂; 4) requiring an oxygen flow of >2 L/min; 5) tachypnea, RR of >50 breaths per min (<1 year old) or RR >40 breaths per min (1–4 years old) ^[22-24].

In the initial stage of NCPAP, patients will receive CPAP at 4–6 cm H_2O and a total flow of either 6–12 L/min (infants) or 8–20 L/min (pediatrics) depending on their age. CPAP, FiO₂, and total flow will be adjusted to achieve target oxygenation and ventilation goals, as described above. If SpO₂ is <92%,

CPAP will be increased by 1–2 cm H₂O (maximum, 10 cm H₂O) and FiO₂ by 0.05–0.10 per increment. For patients with a SpO₂ of >97%, FiO₂ will be decreased first by 0.05 per decrement until FiO₂ is <0.35. If SpO₂ is still >97%, CPAP will be decreased by 1 cm H_2O per decrement. When a CPAP of 2–3 cm H_2O combined with a FiO₂ <0.35 is sufficient to maintain target oxygenation and ventilation goals, patients will be switched to conventional oxygen therapy.

Indications for reintubation are as follows: 1) respiratory acidosis (pH < 7.35 and $PaCO_2 > 45$ mmHg, or an increase in PaCO₂ of >15% compared with pre-extubation level); 2) hypoxemia (FiO₂ > 50%, PaO₂ < 60 mmHg, or SpO₂ < 90%); 3) rapid RR as defined in Table 3; 4) respiratory fatigue and severe dyspnea; 5) inability to maintain the natural airway; 6) persistent respiratory acidosis, hypoxemia, dyspnea even on NCPAP/NIV^[25].

Patients with occurrence of the first indication, the second indication, or any other two indications will Y.C be reintubated.

Table 3. Rapid RR based on ages

Age (years)	Respiratory rate (breaths per min)
<1	>60
1-2	>45
25	>40
>5	>35

Patient termination and withdrawal criteria

At any time, the next of kin can retreat patients from the study. Patients may be withdrawn from the study because of: (1)severe adverse events(barotrauma, arrhythmia and cardiac arrest); or (2) violating or

BMJ Open

deviating from the protocol; or (3) severe hypoxemia who meet the indication of ECMO or HFOV. If a patient is withdrawn for one of the three reasons mentioned, security analysis will be implemented.

Outcomes

The primary outcome is the duration of MV. The duration of MV refers to the time between admission to the ICU and extubation(hours). The secondary endpoints include PaO₂/FiO₂ (mmHg), respiratory system compliance, duration of non-invasive ventilation (from the initiation to the weaning ,hours), reintubation rate in 48 hours after extubation, length of ICU stay(from the admission the ICU to discharge from ICU, days), length of hospital stay(from the admission the hospital to discharge from hospital ,days), occurrence of serious adverse event(barotrauma, arrhythmia and cardiac arrest), postoperative pulmonary complications(respiratory infection, respiratory failure, pleural effusion, pneumothorax, atelectasis, bronchospasm, etc.). Before recruiting subjects, ventilator-free days through day 28 was added as a secondary outcome measure based on the lung recruitment studies in adults with ARDS and reviewers' opinions (If the patient dies before 28 days, ventilator-free days equals 0; If the patient is successfully weaned from mechanical ventilation within 28 days, ventilator-free days equals (28-x); If the patient requires mechanical ventilation for 28 days or more; ventilator-free days equals 0).

Sample size

The duration of mechanical ventilation following cardiac surgery vary substantially across hospitals.^[26] At the same time, no previous studies can be used as a reference.According to the information system data of health care before and after the implementation of RM in our PICU (2019 vs 2020), the average duration of mechanical ventilation in pediatrics after cardiac surgery was 16 hours and 11 hours, respectively. The study sample size was calculated on the basis of an expected 11 hours of MV in the lung recruitment group and 16 hours in the conventional group. Allowing for a 10% dropout rate, 117

patients are required for each group. After reviewing multiple adult lung recruitment studies, we conclude that the sample size of 234 cases will be sufficient^[5 27 28].

Randomization

Patients will be randomized in a 1:1 ratio to a conventional group or to a lung recruitment group. The random allocation list was generated by a statistician with no clinical involvement in the trial using a computer-generated random number list. Then the statistician will use sequentially numbered containers to implement the random allocation sequence, and the treatment allocation group will be hidden beyond the coated card in the container. For patients who meet the required criteria, the investigator will open a randomized card that records the treatment allocation group. Hence, treatment allocation will be r revie concealed.

Patient and Public Involvement

No patient and public involved.

Data collection and inspection

The principal investigators will centralize all data weekly and examine the accuracy of these data to promote data quality. Data collection for each patient will begin on the day that informed consent was received from the patient and will continue until the patient is discharged or transferred to another hospital. Data will be collected using a paper-based case report form (see Online Supplementary files 1-3) and an electronic database. Investigators will follow a schedule for data collection, including: (1) screening data, informed consent, demographic data, inclusion and exclusion criteria, and enrollment data; (2) baseline information (age, sex, ID, height, weight, diagnosis, type of surgery, pulmonary infection, airway stenosis, pulmonary hypertension, duration of cardiopulmonary bypass, Pediatric Risk of Mortality score, Risk Adjustment in Congenital Heart Surgery score(RACHS score), vasoactive-

inotropic score(VIS score), antibiotic therapy); (3) daily information on cardiovascular system (heart rate, blood pressure, central venous pressure, urine output, dosage of vasoactive agents), respiratory system (ventilator settings, PaO₂, PaCO₂, lung compliance), infection (white blood count, procalcitonin, C-reactive protein, interleukin-6), liver function (bilirubin, alanine aminotransferase, aspartate aminotransferase, albumin), renal function (urea nitrogen, creatinine); 4)prognosis: time of admission to ICU , extubation, initiation of NIV and reintubation , date of transferring out of the intensive care unit and date of discharge/death, whichever comes first.

Adverse events

RM related adverse events include transient hypotension (4weeks-1year SBP < 65mmHg, 1year-4years SBP < 70mmHg, 5years-12 years SBP < 80mmHg, >12 years SBP < 90mmHg), hypoxemia (SpO₂ < 84%) for more than 1 minute, and heart rate decreased or increased by more than 20% of the base value. RM won't be continued in those patients with adverse events and will be started again at another time. Severe adverse events include barotrauma (such as, pneumothorax, subcutaneous emphysema, mediastinal emphysema, interstitial emphysema), arrhythmias and cardiac arrest, etc. If severe adverse events happen, patient will be retreated from RM group. All patients who will receive RM will be monitored for blood pressure, SpO₂, and ECG, and will receive physical examination to assess barotrauma in real time. If necessary, lung ultrasound or chest imaging can be performed during or after the RM. Researchers will record and report adverse events and severe adverse events timely, at the same time, appropriate treatment for those adverse events will be prescribed to patients.

Data analysis

Descriptive statistics will be expressed as mean \pm SD or median and interquartile range depending on the nature and distribution of the variables. Inferential statistics will use estimates of the mean of the 13

differences and their 95 % confidence intervals (CI). Variables normally distributed will be compared with the Student's t test. For variables without a normal distribution, the Mann-Whitney U rank test will be used for comparison. Categorical variables will be compared using Fisher's exact test. The primary outcome variable (total duration of MV) and ventilator-free days through day 28 will be assessed with the Student's t test or the Mann-Whitney U rank test dependent on the distribution of the data. The relative risks and their 95 % CIs will be estimated. For all these comparisons, we will consider a difference to be statistically significant if p < 0.05.

Safety and quality control

 Recent studies have demonstrated the efficacy and safety of lung recruitment performed by incremental and decremental PEEP ^[8 10 11]. The study applicants and other primary investigators performed detailed and rigorous lung recruitment, which was applied to more than 200 patients at our pediatric ICU. Each patient demonstrated an increase in PaO₂, improved lung compliance, and a decrease in PaO₂, while none of them showed pneumothorax, subcutaneous emphysema, or other complications.

Ethics and dissemination

The protocol has been registered at the Chinese Clinical Trial registry (registration number: ChiCTR1900025990). Any revisions to the protocol will be documented in the ClinicalTrials.gov registry. Written informed consent has and will be obtained from all patients. All included patients will be able to access and correct the data. In the event of additional studies from the database, all investigators will keep the results confidential until publicly available, and they will not publish any data related to the database without approval of the principal investigator. We will publish the results of this trial in peer reviewed clinical journals and present the findings at conferences for widespread dissemination.

Acknowledgement

We would like to thank TopEdit (www.topeditsci.com) for English language editing of this manuscript.

Author Contributions

LJD and GPL together designed the study. ND and MMG drafted the manuscript. LJD and ND critically revised the manuscript. ND, MMG and WXX contributed to the study development. ND and MMG contributed equally to this paper.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-

profit sectors

Competing interests

None declared.

cation Patient consent for publication

Not required.

Ethics approval

The study has been approved by the ethics committee of West China Hospital, Sichuan University.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data sharing statement

No additional unpublished data are available.

References

1.	Bartz RR, Ferreira RG, Schroder JN, et al. Prolonged pulmonary support after cardiac surgery:
	incidence, risk factors and outcomes: a retrospective cohort study. J Crit Care
	2015; 30 (5):940-44.
2.	Gajic O, Dabbagh O, Park PK, et al. Early Identification of Patients at Risk of Acute Lung
	Injury. Am J Resp Crit Care Med 2011;183(4):462-70.
3.	Lapinsky SE, Mehta S. Bench-to-bedside review: Recruitment and recruiting maneuvers. Crit
	<i>Care</i> 2005; 9 (1):60-5.
4.	Borges JB, Okamoto VN, Matos GF, et al. Reversibility of lung collapse and hypoxemia in
	early acute respiratory distress syndrome. Am J Respir Crit Care Med 2006;174(3):268-78.
5.	Goligher EC, Hodgson CL, Adhikari NKJ, et al. Lung Recruitment Maneuvers for Adult
	Patients with Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis.
	Ann Am Thorac Soc 2017;14(Supplement_4):S304-S11.
6.	Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute
	respiratory distress syndrome. N Engl J Med 2006;354(17):1775–86.
7.	Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European
	Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice
	Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress
	Syndrome. <i>Am J Respir Crit Care Med</i> 2017; 195 (9):1253-63.
8.	Gernoth C, Wagner G, Pelosi P, et al. Respiratory and haemodynamic changes during
	decremental open lung positive end-expiratory pressure titration in patients with acute
	respiratory distress syndrome. Crit Care 2009;13(2):R59.

9.	Boriosi JP, Cohen RA, Summers E, et al. Lung aeration changes after lung recruitment in
	children with acute lung injury: a feasibility study. <i>Pediatr Pulmonol</i> 2012;47(8):771-9.
10.	Boriosi JP, Sapru A, Hanson JH, et al. Efficacy and safety of lung recruitment in pediatric
	patients with acute lung injury. Pediatr Crit Care Med 2011;12(4):431-6.
11.	Duff JP, Rosychuk RJ, Joffe AR. The safety and efficacy of sustained inflations as a lung
	recruitment maneuver in pediatric intensive care unit patients. Intensive Care Med
	2007; 33 (10):1778-86.
12.	Halbertsma FJ, Vaneker M, Pickkers P, et al. A single recruitment maneuver in ventilated
	critically ill children can translocate pulmonary cytokines into the circulation. J Crit Care
	2010; 25 (1):10-15.
13.	Pediatric Acute Lung Injury Consensus Conference G. Pediatric acute respiratory distress
	syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus
	Conference. Pediatr Crit Care Med 2015;16(5):428-39.
14.	Tusman G, H. Böhm S, Tempra A, et al. Effects of recruitment maneuver on atelectasis in
	anesthetized children. Anesthesiology 2003;98(1):14-22.
15.	Jauncey-Cooke J, East CE, Bogossian F. Paediatric lung recruitment: a review of the clinical
	evidence. Paediatr Respir Rev 2015;16(2):127-32.
16.	Kheir JN, Walsh BK, Smallwood CD, et al. Comparison of 2 Lung Recruitment Strategies in
	Children With Acute Lung Injury. Respir Care 2012;58(8):1280-90.
17.	Cruces P, Donoso A, Valenzuela J, et al. Respiratory and hemodynamic effects of a stepwise
	lung recruitment maneuver in pediatric ARDS: a feasibility study. Pediatr Pulmonol
	2013; 48 (11):1135-43.
17	

18.	Marcus RJ, van der Walt JH, Pettifer RJA. Pulmonary volume recruitment restores pulmonary
	compliance and resistance in anaesthetized young children. Paediatr Anaesth 2002;12: 579-
	84.
19.	Wolf GK, Gomez-Laberge C, Kheir JN, et al. Reversal of dependent lung collapse predicts
	response to lung recruitment in children with early acute lung injury. Pediatr Crit Care Med
	2012; 13 (5):509-15.
20.	Kneyber MCJ, de Luca D, Calderini E, et al. Recommendations for mechanical ventilation of
	critically ill children from the Paediatric Mechanical Ventilation Consensus Conference
	(PEMVECC). Intensive Care Med 2017;43(12):1764-80.
21.	Schmidt GA, Girard TD, Kress JP, et al. Liberation From Mechanical Ventilation in Critically
	Ill Adults: Executive Summary of an Official American College of Chest
	Physicians/American Thoracic Society Clinical Practice Guideline. Chest 2017;151(1):160-
	65.
22.	Oymar K, Bardsen K. Continuous positive airway pressure for bronchiolitis in a general
	paediatric ward; a feasibility study. BMC Pediatr 2014;14:122.
23.	Wilson PT, Morris MC, Biagas KV, et al. A randomized clinical trial evaluating nasal
	continuous positive airway pressure for acute respiratory distress in a developing country. J
	Pediatr 2013;162(5):988-92.
24.	Mayordomo-Colunga J, Medina A, Rey C, et al. Non invasive ventilation after extubation in
	paediatric patients: a preliminary study. BMC Pediatr 2010;10:29.

25.	Stucki P, Perez MH, Scalfaro P, et al. Feasibility of non-invasive pressure support ventilation						
	in infants with respiratory failure after extubation a pilot study. Intensive Care Med						
	2009; 35 (9):1623-27.						
26.	Gupta P, Tang X, Gossett JM, et al. Variation of Ventilation Practices With Center Volume						
	After Pediatric Heart Surgery. Clin. Cardiol 2015;38(3):178-84.						
27.	Eronia N, Mauri T, Maffezzini E, et al. Bedside selection of positive end-expiratory pressure						
	by electrical impedance tomography in hypoxemic patients: a feasibility study. Ann Intensive						
	<i>Care</i> 2017; 7 (1):76.						
28.	Kung SC, Hung YL, Chen WL, et al. Effects of Stepwise Lung Recruitment Maneuvers in						
	Patients with Early Acute Respiratory Distress Syndrome: A Prospective, Randomized,						
	Controlled Trial. J Clin Med 2019;8(2).						
Figure 1	. Enrollment and Study Protocol.						
Figure 2. Recruitment maneuver (RM) procedure. The RM will be performed in synchronized							
intermittent mandatory ventilation-pressure control (SIMV-PC) mode with a fixed driving pressure (
of 15 cn	$_{1}H_{2}O$ above positive end-expiratory pressure (PEEP). PEEP will be increased by 5 cmH ₂ O						
every 2	minutes to a maximum of 25 cmH ₂ O. During the decremental phase of the RM, PEEP will be						
optimize	ed to achieve better dynamic compliance (Cdyn; decremental PEEP trial). The PEEP with the						

best Cdyn is called the closing pressure. After the decremental PEEP trial, the RM will be repeated

with a PEEP of 20 cmH₂O and a DP of 15 cmH₂O. The optimal PEEP will be the closing pressure plus

 $2 \text{ cmH}_2\text{O}$. For example, Figure 2 shows that the PEEP with the best Cdyn is $9 \text{ cmH}_2\text{O}$. Thus, PEEP will be set to $11 \text{ cmH}_2\text{O}$.

to beet terien only




Figure 1 Enrollment and Study Protocol




Figure 2. Recruitment maneuver (RM) procedure. The RM will be performed in synchronized intermittent mandatory ventilation-pressure control (SIMV-PC)mode with a fixed driving pressure (DP) of 15 cmH₂O above positive end-expiratory pressure (PEEP). PEEP will be increased by 5 cmH₂O every 2 minutes to a maximum of 25 cmH₂O. During the decremental phase of the RM, PEEP will be optimized to achieve better dynamic compliance (Cdyn; decremental PEEP trial). The PEEP with the best Cdyn is called the closing pressure. After the decremental PEEP trial, the RM will be repeated with a PEEP of 20 cmH₂O and a DP of 15 cmH₂O. The optimal PEEP will be the closing pressure plus 2 cmH₂O. For example, Figure 2 shows that the PEEP with the best Cdyn is 9 cmH₂O. Thus, PEEP will be set to 11 cmH₂O.

patient ID	age	sex	_male□_fem
body weight	kg height	cm ethnic	
Preoperative data			
diagnosis			
pulmonary infec ye	s no pulmonary a	yes (mild /moderate	/s □no
airway stenosis ye	s□ no□		
difficulty airway ye	s□ no□		
Operative data			
operative route mi	iddle incisiclateral incision		
bypass time, mins			
Circulatory arres ye	es no		
Use of bloodpro ye			
postoperative P/F(
ICU Admission			
time	SI	urgery	
diagnosis			
PRISM score	RACHS score		
VIS score in 24 hc	ours	× epinephrine + 10 × I	milrinone + 10
VIS score in 24 hc (VIS score= dopa	ours mine + dobutamine + 100	× epinephrine + 10 × I	milrinone + 10
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)	× epinephrine + 10 × i	milrinone + 10
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)	× epinephrine + 10 × i	milrinone + 10
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)	× epinephrine + 10 × i	milrinone + 10
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)	× epinephrine + 10 × i	milrinone + 10
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		milrinone + 10
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa	ours mine + dobutamine + 100 onepinephrine)		
VIS score in 24 hc (VIS score= dopa Pituitrin+ 100 × no	ours mine + dobutamine + 100 onepinephrine)		

Patient demogra	prines		
patient ID	age	sex	malen female
body weight	kg height	<u> </u>	
Preoperative dat	a		
diagnosis			
pulmonary infecy	/es□ no□ pulmonary a	_ □□yes (mild /moderate	/s □no
airway stenosis	/es□ no□		
difficulty airway	/es□ no□		
Operative data			
operative route i	middle incisiclateral incisio	on⊡	
bypass time, mins		-	
Circulatory arres			
Use of bloodpro		-	
postoperative P/I		-	
ICU Admission			
time		surgery	
diagnosis –			
PRISM score	RACHS score		
(VIS score in $\frac{1}{2}$	4 hours)		
(VIS score in 2 (VIS score= dor	•		milrinone + 10 000
(VIS score= dop	pamine + dobutamine + 10		milrinone + 10 000
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)		milrinone + 10 000
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)		milrinone + 10 000
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)		milrinone + 10 000
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)		milrinone + 10 000
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	milrinone + 10 000
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	
(VIS score= dop Pituitrin+ 100 × r	pamine + dobutamine + 10 nonepinephrine)	00 × epinephrine + 10 × i	

1						
1 2		D0	D1	D2	D3	D4
2 3	Data	DU	DI	DZ	05	04
5 4	Date					
4 5	Circulatory system					
6	HR (beat/min)					
7	BP (mmHg)					
8	· •					
9	mean BP(mmHg)					
10	CVP (mmHg)					
11	fluid input (ml)					
12	fluid output (ml)					
13						
14						
15	dopamine µg/ (kg·min)					
16	milrinone µg/ (kg·min)					
17	epinephrine µg/ (kg·min					
18	nonepinephrine μg/ (kg·					
19 20						
20 21	pituitrinµg/ (kg∙min)					
21	Respiratory system					
22 23	ventilation mode					
23 24	f (/min)					
25						
26	Pi (cmH ₂ O)					
27	PEEP(cmH ₂ O)					
28	FiO ₂					
29	_					
30	PaO ₂					
31	PaO_2/FiO_2					
32	SaO ₂					
33 34	_					
34 35	Laboratory examination					
36	ABG					
37	рН					
38	PaO_2 (mmHg)					
39						
40	PaCO ₂ (mmHg)					
41	BE					
42	HCO_3^- (mmHg)					
43	Lac (mmol/L)					
44						
45 46	Infectious index					
46 47	WBC (X10 ⁹)					
47 48	PCT					
48 49	CRP					
50						
51						
52	Liver function					
53	bilirubin					
54	ALT					
55						
56	AST					
57	ALB (g/L)					
58						
59	Earna	or rovious only	http://bmianan	hmi com/site/a	bout/auidelines	vhtml
60	FULDER		IIIIUUUUU	.viiii.cuiii/Sile/d	NOUL AURTHES	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Renal function						
BUN						
CREA (umol/L)						
Blood routine examinatio	n					
Plt						
Hb (g/L)						
	D0	D1	D2	2	D3	D4
date						
Etiological data						
positive sputum culture	yes⊡ no	o yes	no□ ye	s□ no□	yes□ no□	yes□ no□
pathogen						
Respiratory virus test						
influenza a virus	yes no		-		-	yes□ no□
adenovirus	yes□ no		-		-	yes□ no□
Bocavirus	yes⊡ no				-	yes□ no□
rhinovirus	yes□ no		•		-	yes□ no□
H1N1	yes⊡ no	-	· ·		-	yes□ no□
Parainfluenza viru	yes⊡ no	-			-	yes□ no□
chlamydia	yes⊡ no	-			-	yes□ no□
Human metapneumovirus influenza B virus	•	-			-	yes□ no□
	yes□ no	-			-	yes□ no□
Mycoplasma pneumoniae H3N2	-	•			-	yes□ no□
coronavirus	yes□ no	•			-	yes□ no□
respiratory syncytial virus	yes□ no	-	-		-	yes□ no□
TORCH	yesu in	o yes yes	•	s□ no□	yes□ no□	yes□ no□
tomegalovirus antibody Ig	,	yes 🗆				
Rubella virus antibody IgN	-	yes⊡				
lex virus antibody type I/II		yes yes				
oplasma antibody(Tox-Ab)		yes⊡				
Imaging finding		,000				
new or progressive infiltra	eves⊡ no	o yes	no□ ve	s no	yes□ no□	yes□ no□
Body temperature (°C)	,	,	,		,	,
highest body temperature	2					
lowest body temperature						
Earnaa	r roviow o	nlv_http://br	nionon hmi	com/site/abo	ut/auidalinas y	html
For pee	i ieview O	my - mup://br	пјореп.оттј.	.com/site/abc	out/guidelines.x	

$1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 39 \\ 39 \\ 31 \\ 31 \\ 31 \\ 31 \\ 31 \\ 31$	Date Circulatory system HR (beat/min) BP (mmHg) mean BP (mmHg) fluid input (ml) fluid output (ml) fluid output (ml) dopamine $\mu g/$ (kg·min milrinone $\mu g/$ (kg·min epinephrine $\mu g/$ (kg·min) Respiratory system ventilation mode f (/min) Pi (cmH ₂ O) PEEP (cmH ₂ O) FiO ₂ PaO ₂ PaO ₂ /FiO ₂ SaO ₂ Laboratory examination ABG pH PaO ₂ (mmHg) PaCO ₂ (mmHg)) in) g·r	D6	D7	D9
36 37 38	pH PaO ₂ (mmHg) PaCO ₂ (mmHg) BE HCO ₃ ⁻ (mmHg) Lac (mmol/L) Infectious index WBC (X10 ⁹) PCT CRP Liver function bilirubin ALT AST ALB (g/L)	beer review only -			s.xhtml

Renal function										
BUN										
CREA (umol/L)										
Blood routine examinatio	n									
Plt										
Hb (g/L)										
	D5		D6		D7		D8		D9	
date										
Etiological data positive sputum culture <i>J</i>		no□		no⊓		no□		no⊓		no
pathogen	yes□	nol	yes□	noli	yes□	no⊔	yes□	noli	yes□	no
Respiratory virus test										
influenza a virus	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
adenovirus	yes□		yes□		yes□		yes□		yes□	
Bocavirus	, yes□		, yes□		, yes□		yes□		, yes□	
rhinovirus	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	
H1N1	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
Parainfluenza viru	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
chlamydia	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
Human metapneumovirus	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
influenza B virus	yes□		yes□		yes□		yes□		yes□	
Mycoplasma pneumoniae	•		yes□		yes□		yes□		yes□	
H3N2	yes□		yes□		yes		yes□		yes□	
coronavirus	yes□		yes□		yes□		yes□		yes□	
respiratory syncytial virus TORCH	yes⊔	nol	yes□ yes□		yes□	nol	yes□	noli	yes□	no
tomegalovirus antibody Ig	,		усз⊔							
Rubella virus antibody IgM										
lex virus antibody type I/II										
oplasma antibody(Tox-Ab)										
Imaging finding										
new or progressive infiltra	yes□	no□	yes□	no□	yes□	no□	yes□	no□	yes□	no
Body temperature $(^{\circ}C)$										
highest body temperature										
lowest body temperature										
For pee	r reviev	w only - h	ttp://b	mjopen.l	omj.cor	n/site/a	bout/gu	idelines.	khtml	

BMJ Open

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to

include the missing information. If you are certain that an item does not apply, please write "n/a" and

provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A,

Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D, SPIRIT 2013 Explanation and

Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Page Reporting Item Number Administrative information Title #1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 30 of 38

1 2	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered,	3
3 4 5			name of intended registry	
6 7	Trial registration:	<u>#2b</u>	All items from the World Health Organization Trial	3
8 9 10 11	data set		Registration Data Set	
12 13 14	Protocol version	<u>#3</u>	Date and version identifier	3
15 16 17 18 19	Funding	<u>#4</u>	Sources and types of financial, material, and other support	15
20 21	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	1,15
22 23 24	responsibilities:			
25 26 27	contributorship			
28 29	Roles and	<u>#5b</u>	Name and contact information for the trial sponsor	N/A no
30 31	responsibilities:			funding
32 33 34	sponsor contact			
34 35 36 37	information			
38 39	Roles and	<u>#5c</u>	Role of study sponsor and funders, if any, in study	N/A no
40 41	responsibilities:		design; collection, management, analysis, and	funding
42 43	sponsor and funder		interpretation of data; writing of the report; and the	
44 45 46			decision to submit the report for publication, including	
40 47 48			whether they will have ultimate authority over any of	
49 50 51			these activities	
52 53 54	Roles and	<u>#5d</u>	Composition, roles, and responsibilities of the	N/A no
54 55 56	responsibilities:		coordinating centre, steering committee, endpoint	funding
57 58	committees		adjudication committee, data management team, and	
59 60		For peer r	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 31 d	of 38
-----------	-------

5			·	
1			other individuals or groups overseeing the trial, if	
2 3			applicable (see Item 21a for data monitoring	
4 5 6			committee)	
7 8	Introduction			
9 10				
11 12	Background and	<u>#6a</u>	Description of research question and justification for	5
13 14	rationale		undertaking the trial, including summary of relevant	
15 16			studies (published and unpublished) examining	
17 18 19			benefits and harms for each intervention	
20				_
21 22	Background and	<u>#6b</u>	Explanation for choice of comparators	5
23 24	rationale: choice of			
25 26 27	comparators			
28 29	Objectives	#7	Specific objectives or hypotheses	5
30 31		<u></u>		Ū
32 33	Trial design	<u>#8</u>	Description of trial design including type of trial (eg,	6
34 35			parallel group, crossover, factorial, single group),	
36 37			allocation ratio, and framework (eg, superiority,	
38 39			equivalence, non-inferiority, exploratory)	
40 41	Methods:			
42 43				
44 45 46	Participants,			
47 48	interventions, and			
49 50	outcomes			
51 52	Study setting	<u>#9</u>	Description of study settings (eg, community clinic,	6
53 54			academic hospital) and list of countries where data will	
55 56			be collected. Reference to where list of study sites can	
57 58 59				
60		For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2			be obtained	
3 4	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If	6
5 6 7			applicable, eligibility criteria for study centres and	
, 8 9			individuals who will perform the interventions (eg,	
10 11 12			surgeons, psychotherapists)	
13 14	Interventions:	<u>#11a</u>	Interventions for each group with sufficient detail to	7-8
15 16 17	description		allow replication, including how and when they will be	
18 19 20			administered	
21 22	Interventions:	<u>#11b</u>	Criteria for discontinuing or modifying allocated	10-11
23 24	modifications		interventions for a given trial participant (eg, drug dose	
25 26			change in response to harms, participant request, or	
27 28 29 30			improving / worsening disease)	
31 32	Interventions:	<u>#11c</u>	Strategies to improve adherence to intervention	8
33 34	adherance		protocols, and any procedures for monitoring	
35 36 37			adherence (eg, drug tablet return; laboratory tests)	
38 39 40	Interventions:	<u>#11d</u>	Relevant concomitant care and interventions that are	7-11
40 41 42 43	concomitant care		permitted or prohibited during the trial	
44 45	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the	11
46 47			specific measurement variable (eg, systolic blood	
48 49			pressure), analysis metric (eg, change from baseline,	
50 51 52			final value, time to event), method of aggregation (eg,	
53 54			median, proportion), and time point for each outcome.	
55 56			Explanation of the clinical relevance of chosen efficacy	
57 58			and harm outcomes is strongly recommended	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including	5
3 4			any run-ins and washouts), assessments, and visits for	
5 6 7			participants. A schematic diagram is highly	
7 8 9 10			recommended (see Figure)	
10 11 12	Sample size	<u>#14</u>	Estimated number of participants needed to achieve	11-12
13 14			study objectives and how it was determined, including	
15 16			clinical and statistical assumptions supporting any	
17 18 19 20			sample size calculations	
20 21 22	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment	11-12
23 24 25			to reach target sample size	
26 27	Methods:			
28 29 30	Assignment of			
31 32	interventions (for			
22				
33 34 35	controlled trials)			
34 35 36 37		<u>#16a</u>	Method of generating the allocation sequence (eg,	12
34 35 36 37 38 39		<u>#16a</u>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any	12
34 35 36 37 38 39 40 41	Allocation: sequence	<u>#16a</u>		12
34 35 36 37 38 39 40	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	Allocation: sequence	<u>#16a</u>	computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol	12
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 	Allocation: sequence generation		computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	
 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 	Allocation: sequence generation Allocation		computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions Mechanism of implementing the allocation sequence	

1 2			sequence until interventions are assigned	
3 4 5	Allocation:	<u>#16c</u>	Who will generate the allocation sequence, who will	12
6 7	implementation		enrol participants, and who will assign participants to	
, 8 9 10			interventions	
11 12	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions	12
13 14			(eg, trial participants, care providers, outcome	
15 16 17 18			assessors, data analysts), and how	
19 20	Blinding (masking):	<u>#17b</u>	If blinded, circumstances under which unblinding is	N/A, always
21 22	emergency		permissible, and procedure for revealing a participant's	be blinded
23 24	unblinding		allocated intervention during the trial	
25 26 27 28	Methods: Data			
29 30	collection,			
31 32	management, and			
33 34	analysis			
35 36 37	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome,	12-13
38 39 40			baseline, and other trial data, including any related	
41 42			processes to promote data quality (eg, duplicate	
43 44			measurements, training of assessors) and a	
45 46			description of study instruments (eg, questionnaires,	
47 48			laboratory tests) along with their reliability and validity,	
49 50 51			if known. Reference to where data collection forms can	
52 53 54			be found, if not in the protocol	
55 56	Data collection plan:	<u>#18b</u>	Plans to promote participant retention and complete	12-13
57 58	retention		follow-up, including list of any outcome data to be	
59 60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 35 of 38

1 2			collected for participants who discontinue or deviate	
3 4 5			from intervention protocols	
6 7	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage,	12-13
8 9			including any related processes to promote data quality	
10 11			(eg, double data entry; range checks for data values).	
12 13			Reference to where details of data management	
14 15 16			procedures can be found, if not in the protocol	
17 18 19	Statistics: outcomes	<u>#20a</u>	Statistical methods for analysing primary and	13-14
20 21			secondary outcomes. Reference to where other details	
22 23			of the statistical analysis plan can be found, if not in the	
24 25 26			protocol	
27 28 29	Statistics: additional	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and	N/A no
30 31	analyses		adjusted analyses)	subgroup
32 33				analyses
34 35	Statistics: analysis	<u>#20c</u>	Definition of analysis population relating to protocol	N/A
36 37 38	population and	<u>#200</u>	non-adherence (eg, as randomised analysis), and any	
39 40	missing data		statistical methods to handle missing data (eg, multiple	
41 42			imputation)	
43 44			inputation	
45 46 47	Methods: Monitoring			
48 49	Data monitoring:	<u>#21a</u>	Composition of data monitoring committee (DMC);	14
50 51 52	formal committee		summary of its role and reporting structure; statement	
52 53 54			of whether it is independent from the sponsor and	
55 56			competing interests; and reference to where further	
57 58			details about its charter can be found, if not in the	
59			eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	
60	F	or peer re	wew only http://biljopen.bilj.com/site/about/guidenites.xitim	

1			protocol. Alternatively, an explanation of why a DMC is	
2 3 4			not needed	
5 6	Data monitoring:	<u>#21b</u>	Description of any interim analyses and stopping	N/A No
7 8 9	interim analysis		guidelines, including who will have access to these	interim
10 11			interim results and make the final decision to terminate	results
12 13			the trial	
14 15				
16 17	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and	13
18 19			managing solicited and spontaneously reported	
20 21			adverse events and other unintended effects of trial	
22 23			interventions or trial conduct	
24 25				N1/A
26 27	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if	N/A
28 29			any, and whether the process will be independent from	
30 31			investigators and the sponsor	
32 33 34	Ethics and			
34 35 36	dissemination			
37				
38 39 40	Research ethics	<u>#24</u>	Plans for seeking research ethics committee /	14
41 42	approval		institutional review board (REC / IRB) approval	
43 44	Protocol	#25	Plans for communicating important protocol	14
45 46		<u>#23</u>		14
47 48	amendments		modifications (eg, changes to eligibility criteria,	
49 50			outcomes, analyses) to relevant parties (eg,	
51 52			investigators, REC / IRBs, trial participants, trial	
53 54			registries, journals, regulators)	
55 56 57 58	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from	14
59 60	I	For peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4			potential trial participants or authorised surrogates, and how (see Item 32)	
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	15
28 29 30 31 32 33 34	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	15
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
	Dissemination policy: trial results		Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
60	F	or peer re	eview only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 38 of 38

1 2	Dissemination policy:	<u>#31b</u>	Authorship eligibility guidelines and any intended use	15
3 4 5	authorship		of professional writers	
6 7 8	Dissemination policy:	<u>#31c</u>	Plans, if any, for granting public access to the full	15
9 10	reproducible		protocol, participant-level dataset, and statistical code	
11 12 13	research			
14 15 16	Appendices			
17 18	Informed consent	<u>#32</u>	Model consent form and other related documentation	Appendices
19 20 21	materials		given to participants and authorised surrogates	
22 23	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage	N/A
24 25 26			of biological specimens for genetic or molecular	
27 28			analysis in the current trial and for future use in	
29 30			ancillary studies, if applicable	
31 32				
33 34	None The SPIRIT che	cklist is	distributed under the terms of the Creative Commons Att	ribution
35 36	License CC-BY-ND 3.0	0. This	checklist can be completed online using <u>https://www.gooc</u>	<u>lreports.org/</u> , a
37 38	tool made by the EQU	ATOR	Network in collaboration with Penelope.ai	
39 40				
41 42				
43 44				
45 46				
47				
48 49				
50 51				
52				
53 54				
55				
56 57				
58 59				
59 60	Fo	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	